White Paper - Transcriptome-informed Drug Design: A Tale of Six Compounds
- Categories
- White Papers
- Therapeutics
A Proof-of-concept Exploration of Transcriptome-informed
Drug Discovery Using the HTG Transcriptome Panel
Comparison of Prototype HTG Transcriptome Panel to RNA-Seq
HTG EdgeSeq™ Reveal Immunophenotyping Signatures
Development and Verification of the HTG EdgeSeq™ Reveal Immune, Stroma and TME Signatures
Proof-of-Concept for a Whole Transcriptome Panel Using HTG EdgeSeq™ Technology
Read how the HTG EdgeSeq technology is a competitive alternative to RNA-Seq
Numerous mutations have been shown to drive oncogenesis in non-small cell lung cancer (NSCLC). Measuring these events with conventional methods is difficult given the small amount of material typically collected in the standard needle core biopsy or similar tissue collection method.
A Research Use Only Content Guide for ALK, ROS1, RET, NTRK1, HER2 and cMET Data Generated from the HTG EdgeSeq ALKPlus Assay EU
Detection of clinically relevant gene fusions with the HTG EdgeSeq ALKPlus Assay EU
Page last updated May 22, 2023